Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Shareholders' Equity / Members' Deficit

v3.20.4
Condensed Consolidated Statements of Shareholders' Equity / Members' Deficit - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Shares
Additional  Paid-In Capital
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Mar. 31, 2019     0        
Beginning balance at Mar. 31, 2019 $ (390,258)   $ 0 $ (184,546) $ (176,002)   $ (29,710)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Foreign currency translation 2,165           2,165
Reclassification of related party payable upon reorganization 600,622     600,622      
Issuance of common stock in connection with initial public offering, net of underwriters' discounts and commissions and issuance costs (in shares)     38,873,000        
Issuance of common stock in connection with initial public offering, net of underwriters' discounts and commissions and issuance costs 585,297   $ 39 585,258      
Effect of reorganization (in shares)     241,547,000        
Effect of reorganization 278,248   $ 242 271,383     6,623
Contribution for taxes associated with reorganization 265,000     265,000      
Restricted stock units vested (in shares)     393,000        
Restricted stock awards forfeited (in shares)     (28,000)        
Share-based compensation 22,992     22,992      
Equity repurchases (150)     (150)      
Net income (loss) (464,726)       (464,726)    
Ending balance (in shares) at Dec. 31, 2019     280,785,000        
Ending balance at Dec. 31, 2019 899,190   $ 281 1,560,559 (640,728)   (20,922)
Beginning balance (in shares) at Sep. 30, 2019     280,509,000        
Beginning balance at Sep. 30, 2019 886,282   $ 281 1,547,051 (642,491)   (18,559)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Foreign currency translation (2,363)           (2,363)
Restricted stock units vested (in shares)     304,000        
Restricted stock awards forfeited (in shares)     (28,000)        
Share-based compensation 13,513     13,513      
Equity repurchases (5)     (5)      
Net income (loss) 1,763       1,763    
Ending balance (in shares) at Dec. 31, 2019     280,785,000        
Ending balance at Dec. 31, 2019 899,190   $ 281 1,560,559 (640,728)   (20,922)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Shareholders' equity $ 961,497 $ 306 $ 281 1,573,347 (594,026) $ 306 (18,105)
Beginning balance (in shares) at Mar. 31, 2020 280,853,040   280,853,000        
Beginning balance at Mar. 31, 2020 $ 961,497 306 $ 281 1,573,347 (594,026) 306 (18,105)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Foreign currency translation (9,920)           (9,920)
Restricted stock units vested (in shares)     1,035,000        
Restricted stock awards forfeited (in shares)     (103,000)        
Issuance of common stock related to employee stock purchase plan (in shares)     331,000        
Issuance of common stock related to employee stock purchase plan $ 9,195     9,195      
Exercise of stock options (in shares) 427,000   427,000        
Exercise of stock options $ 6,849     6,849      
Share-based compensation 43,091     43,091      
Equity repurchases (36)     (36)      
Shareholders' equity $ 1,059,742 $ 306 $ 281 1,632,446 (594,026) $ 306 (18,105)
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201602Member            
Net income (loss) $ 48,760       48,760    
Ending balance (in shares) at Dec. 31, 2020 282,542,649   282,543,000        
Ending balance at Dec. 31, 2020 $ 1,059,742   $ 281 1,632,446 (544,960)   (28,025)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Shareholders' equity 1,022,912   $ 281 1,609,246 (563,376)   (23,239)
Beginning balance (in shares) at Sep. 30, 2020     282,024,000        
Beginning balance at Sep. 30, 2020 1,022,912   $ 281 1,609,246 (563,376)   (23,239)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Foreign currency translation (4,786)           (4,786)
Restricted stock units vested (in shares)     229,000        
Restricted stock awards forfeited (in shares)     (7,000)        
Issuance of common stock related to employee stock purchase plan (in shares)     172,000        
Issuance of common stock related to employee stock purchase plan 5,603     5,603      
Exercise of stock options (in shares)     125,000        
Exercise of stock options 2,020     2,020      
Share-based compensation 15,588     15,588      
Equity repurchases (11)     (11)      
Shareholders' equity 1,059,742   $ 281 1,632,446 (544,960)   (28,025)
Net income (loss) $ 18,416       18,416    
Ending balance (in shares) at Dec. 31, 2020 282,542,649   282,543,000        
Ending balance at Dec. 31, 2020 $ 1,059,742   $ 281 1,632,446 (544,960)   (28,025)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Shareholders' equity $ 1,059,742   $ 281 $ 1,632,446 $ (544,960)   $ (28,025)